** Shares of Telix Pharmaceuticals TLX.AX rise as much as 3.2% to a record high of A$29.610; last up 2.6%

** The biopharma co says it does not expect business to be affected by the current international trade tariffs levied by the U.S. Government

** Co currently generates most of its revenue from U.S. sales of Illuccix, its prostrate cancer diagnostic drug

** Stock climbed 19.2% in January

(Reporting by Manasi Dasa Sundeep in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))